Αρχική World News Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from... World News Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Από Ogkologos - 8 Σεπτεμβρίου, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NSABP B-59/GeparDouze study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Laser-Based Device Detects and Kills Melanoma Cells in the Blood, Study... 25 Ιουλίου, 2019 Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... 9 Αυγούστου, 2022 India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration 7 Φεβρουαρίου, 2024 Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma 19 Ιανουαρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or... ESMO World Congress on Gastrointestinal Cancer 2020 ASCO 2021 news: follow-up treatments pave the way